Samsung Biologics has completed the acquisition of a biologics manufacturing facility in Rockville, Maryland from GSK, marking its first manufacturing presence in the United States.

The Rockville site includes two cGMP-compliant manufacturing plants with a combined drug substance capacity of 60,000 liters. The facility supports both clinical and commercial biologics production across multiple scales. With this addition, Samsung Biologics’ total global manufacturing capacity has increased to 845,000 liters.

Under the terms of the agreement, Samsung Biologics will continue supplying products previously manufactured at the site to GSK, while gradually transitioning the facility to serve broader contract manufacturing requirements.

The company also plans to invest further in expanding capacity and upgrading technologies at the site, reinforcing its commitment to building a more resilient global supply chain and improving access to critical medicines.

“This marks an important step in expanding our US footprint,” said John Rim, President and CEO of Samsung Biologics. “The Rockville site enhances our geographically diversified manufacturing network, and we are pleased to welcome over 500 experienced professionals to our global team. Their expertise will be instrumental in strengthening our operations and supporting our mission to deliver high-quality therapies to patients worldwide.”

The acquisition follows the agreement announced on December 22, 2025.

Samsung Biologics is a leading contract development and manufacturing organization (CDMO), offering integrated services from late-stage development to commercial production. Prior to this acquisition, the company operated a combined biomanufacturing capacity of 785,000 liters across its Bio Campus I and II facilities in Korea.

With additional land secured for Bio Campus III, Samsung Biologics is preparing for future expansion to support next-generation therapies and emerging modalities, including multispecific antibodies, antibody-drug conjugates, fusion proteins, and mRNA therapeutics.

The company continues to strengthen its global network across Korea, the US, and Japan, supported by standardized manufacturing processes and advanced digital systems under its ExellenS framework. This ensures operational consistency, flexibility, and high-quality delivery for global partners.

Through ongoing investments and innovation, Samsung Biologics aims to enhance manufacturing agility while ensuring reliable, on-time delivery of biopharmaceutical products worldwide.